The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed. Read my analysis of ROIV stock.

Just as Andrew Witty of UnitedHealth Group did in a call with investors last month, CVS Health’s CEO David Joyner defended ...

the Humira molecule was losing patients to other novel mechanisms and Skyrizi and Rinvoq were picking up some of that. It's not what's driving the momentum for Skyrizi and Rinvoq, but it certainly ...

The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...

we continue to see molecule compression in the U.S. with volume moving to other novel mechanisms, which has resulted in a benefit to both Skyrizi and Rinvoq. We anticipate Humira access will ...

Rova-T had a convincing-looking mechanism of action ... were in the region of $5 billion per year at peak. It wasn’t a Humira, but AbbVie was realistic enough to accept that it was unlikely ...

Humira's origins lie in the phage display technology ... in broader indications that have a similar underlying molecular mechanism. Ilaris has initially gained approval in familial cold auto ...

Through its mechanism Humira controls HS flare-ups and enhances patients’ skin health together with their quality of life in treating this persistent skin disease. Cosentyx (Secukinumab): Novartis The ...

Background: Matching disease and treatment mechanisms is a goal of the Precision Medicine ... Adalimumab (brand names Humira, Amgevita, Hyrimoz, Idacio, Imraldi, and Yuflyma), which is used to treat ...